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Abstract The purpose of this study was to examine the prog-
nostic impact of corticosteroids in hemodynamically stabile
Staphylococcus aureus bacteremia (SAB). There were 361
hemodynamically stabile methicillin-sensitive SAB patients
with prospective follow-up and grouping according to time-
point, dose and indication for corticosteroid therapy. To enable
analyses without external interfering corticosteroid therapy all
patients with corticosteroid therapy equivalent to prednisone
>10 mg/day for ≥1 month prior to positive blood culture re-
sults were excluded. Twenty-five percent (92) of patients re-
ceived corticosteroid therapy of which 11 % (40) had therapy
initiated within 1 week (early initiation) and 9 % (31) had
therapy initiated 2–4 weeks after (delayed initiation) positive
blood culture. Twenty-one patients (6 %) had corticosteroid
initiated after 4 weeks and were not included in the analyses.
A total of 55 % (51/92) received a weekly prednisone dose
>100 mg. Patients with early initiated corticosteroid therapy
had higher mortality compared to patients treated without cor-
ticosteroid therapy at 28 days (20 % vs. 7 %) (OR, 3.11;
95%CI, 1.27–7.65; p<0.05) and at 90 days (30 % vs. 10 %)
(OR, 4.01; 95%CI, 1.82–8.81; p<0.001). Considering all
prognostic markers, early initiated corticosteroid therapy pre-
dicted 28-day (HR, 3.75; 95%CI, 1.60–8.79; p=0.002) and
90-day (HR, 3.10; 95%CI, 1.50–6.39; p=0.002) mortality in
Cox proportional hazards regression analysis. When including
only patients receiving early initiated corticosteroid therapy
with prednisone ≥100 mg/week the negative prognostic im-
pact on 28-day mortality was accentuated (HR 4.8, p=0.001).
Corticosteroid therapy initiation after 1 week of positive blood
cultures had no independent prognostic impact. Early initia-
tion of corticosteroid therapy may be associate to increased
mortality in hemodynamically stabile SAB.
Introduction
Staphylococcus aureus is one of the most common bacteremic
pathogens and associated with considerable mortality of 12–
32% in recent studies [1, 2]. The prognosis of Staphylococcus
aureus bacteremia (SAB) is dictated by severe underlying
conditions such as immunosuppression and corticosteroid
therapy [3–6], severe sepsis and septic shock [4, 7], deep
infection foci such as endocarditis [1, 8] and methicillin-
resistance [1, 9]. Recently, over 70 % of SAB patients have
had deep infection foci diagnosed [3, 8].
Hemodynamic instability, i.e. severe sepsis or septic shock,
is encountered in 10–38 % of SAB patients [4, 7]. The role of
corticosteroids in the management of severe sepsis and septic
shock is continuously debated. Experimental studies have re-
lated the potential therapeutic impact of corticosteroids in se-
vere infections to various molecular mechanisms such as pre-
vention of release of interleukin-1 [10] or tumor necrosis fac-
tor [11] from mononuclear cells. The first clinical studies in
1976 suggested improved survival with high dose corticoste-
roid [12] but subsequent randomized-controlled trials failed to
confirm these results [13–16]. In the late 1990s and early
2000s prolonged low-dose hydrocortison treatment improved
survival in several studies [17, 18], including a meta-analysis
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[19]. However, further studies with severe sepsis or septic
shock have demonstrated that corticosteroids do not affect
28-daymortality whereas long course treatment with low dose
corticosteroids may reduce 28-day all-cause mortality [20],
and a recent meta-analysis associated high-dose corticosteroid
treatment to an indifferent or higher mortality probability and
low-dose corticosteroid treatment to a lower mortality proba-
bility [21].
Corticosteroids may be used in hemodynamic stabile SAB
patients for various reasons although their impact on patient
outcome has not been studied. In bacteremic patients under-
lying conditions such as rheumatic diseases or chronic pulmo-
nary diseases may necessitate corticosteroid therapy due to
exacerbation or non-suitability of other treatment options [4,
6, 22–24]. Corticosteroids may be needed in the management
of neurosurgical procedures like subdural hematoma [25, 26]
in which operative treatment may predispose patients to SAB.
There are also SAB-related indications for corticosteroid treat-
ment such as epidural abscesses, to relieve myeloid compres-
sion [27], or SAB-induced immune complex glomerulone-
phritis [28]. It has not been evaluated how common the use
of corticosteroids during SAB treatment is and how it affects
outcome in hemodynamic stabile patients.
The objective of this study was to investigate the indica-
tions, initiation time-point, dose and prognostic impact of ad-
junctive corticosteroid therapy in hemodynamic stabile SAB
patients. The inclusion of methicillin-sensitive S. aureus
strains only enabled a study setting without the impact of
differences in empirical antibiotic therapy.
Materials and methods
Settings and study population
This was a prospective multicenter study including adult pa-
tients with at least one positive blood culture for S. aureus
from five university and seven tertiary care central hospitals
in Finland [22]. To enable thorough analyses without any
external interfering corticosteroid therapy, all patients with
corticosteroid therapy equivalent to prednisone≥10 mg/day
for≥1 month prior to positive blood culture and all patients
with severe sepsis or septic shock receiving systemic cortico-
steroid as part of sepsis therapy at blood culture collection
time-point were excluded. Further exclusion criteria were:
age<18 years, pregnancy, breastfeeding, imprisonment, epi-
lepsy, bacteremia 28 days prior to the study, polymicrobial
bacteremia and meningitis [22, 29]. No cases of methicillin-
resistant S. aureus (MRSA) were accepted (N=6). There was
a three-day median time-period between blood culture sam-
pling and study inclusion. Data collection included the follow-
ing parameters: age, gender, SAB acquisition, underlying dis-
eases and McCabe’s classification, length and administration
route of antibiotic therapy and any corticosteroid therapy.
Documentation of infection foci were based on clinical suspi-
cion or verified by bacteriological, pathological or radiologi-
cal findings. Laboratory findings, radiological investigations
and time to defervescence (axillary temperature below 37.5
°C) were recorded. Primary endpoint was mortality at 28 or at
90 days. Secondary endpoints were prevalence of deep infec-
tion foci and time to defervescence.
Antibiotic therapy
The standard antibiotic therapy was a semisynthetic penicillin.
Patients with contradictions for penicillin were provided with
cefuroxime, clindamycin or vancomycin. Furthermore, fluo-
roquinolone and rifampicin served as additional antibiotic
therapy. Length of antibiotic therapy was considered proper
when administered intravenously for at least 28 days for a
deep infection focus and 14 days in the absence of any deep
infection. Detailed information on antimicrobial therapy indi-
cations, dosage and administration routes has been provided
earlier [29, 30].
Follow-up time period
The prospective follow-up time for the study was 90 days. No
patients were lost during the follow-up. Patients that were
transferred to other hospitals during the study were followed
by direct communication with hospital staff and by thorough
patient record retrieval. A follow-up visit at the outpatient
policlinic was arranged for each patient who was not hospital-
ized at 90 days.
Definitions
Healthcare-associated (HA) SAB was defined as bacteremia
with the first positive blood culture for S. aureus
obtained≥48 hours after hospital admission or when the pa-
tient had remained in a long-term care facility or undergone
hemodialysis within the preceding two months. McCabe’s
criteria were used to classify underlying diseases [31]. Deep
infection foci were defined as pneumonia, endocarditis, puru-
lent arthritis, osteomyelitis, deep-seated abscess and foreign-
body infections. Severe sepsis was classified as sepsis in com-
bination with hypotension, hypoperfusion, or organ failure
and septic shock as sepsis with arterial hypotension despite
adequate fluid resuscitation [32].
Corticosteroid therapy
Corticosteroid therapies were started on a clinical basis and
were documented and altered into equivalent doses of predni-
sone. Therapy was grouped according to (1) onset time-point,
(2) cumulative weekly dosage and (3) indication for therapy.
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Initiation time-point was grouped into (i) early initiation (ther-
apy onset within the first week of positive blood culture), (ii)
delayed initiation (therapy onset within 2–4 weeks after pos-
itive blood culture) and (iii) late initiation (therapy onset past
4 weeks of positive blood culture).
Statistical analysis
Categorical variables were compared with Pearson’s X² test
and non-parametric data were analyzed with Mann-Whitney
U-test. Odds ratios (OR) with 95 % confidence intervals (CI)
were calculated. Univariate factors with p<0.05 were accept-
ed for Cox proportional hazards regression model analysis of
factors predicting mortality, and hazard ratios (HR) with 95 %
confidence intervals (CI) were calculated. The Kaplan-Meier
method was applied for survival estimates. Analyses were
done using SPSS version 12.0 (SPSS Inc., Chicago, IL,
USA). All tests were two-tailed and p<0.05 was considered
as significant.
Results
Patient characteristics
Altogether 430 patients with SAB were included. When ac-
counting for pre-bacteremic corticosteroid use and patients
with severe sepsis or septic shock, 69 patients were excluded
and 361 hemodynamically stabile methicillin-sensitive SAB
patients were accepted for the study (Fig. 1).
Adjunctive corticosteroid therapy
Ninety-two (25 %) of 361 SAB patients received corticoste-
roid therapy of whom 40 (11 %) had the therapy initiated
within one week (early initiation) and 31 (9 %) within 2–
4 weeks (delayed initiation). Furthermore, in 21 (6 %) patients
the corticosteroid treatment was initiated after 4 weeks (late
initiation) of positive blood culture and these patients were not
included in the analyses. Altogether 269 (75 %) patients were
treated without corticosteroid therapy (Fig. 1 and Table 1).
The weekly mean cumulative corticosteroid dose (± standard
deviation) was 276±436 mg prednisone during the first week
and weekly corticosteroid doses of at least 100 mg were re-
ceived by 26/92 (65 %) patients during the first week and by
12/92 (39 %) patients during weeks 2 to 4.
Indications for corticosteroid therapy were recorded from
the patient records and in detail analyzed for patients with
early initiated corticosteroid therapy (Table 2). In 7 (17 %)
patients the indication could not be reliably retrieved. The
most common indication was the suspicion or diagnosis of
an immunological phenomenon including 30 % of patients,
either (i) activation of an earlier diagnosed autoimmune
disease (e.g. ancylosing spondylitis), (ii) a reactive process
(e.g. reactive arthritis) or (iii) the suspicion of an immunolog-
ical defect. Among 20 % of patients, early initiated corticoste-
roid therapy was due to an exacerbation of a pulmonary dis-
ease or due to a pleural effusion. In 17 % of cases, corticoste-
roid therapy was initiated early due to epidural-, para-spinal-
or pre-sacral abscesses; however, this did not impact mortality.
Altogether 6 (16 %) patients had corticosteroid therapy initi-
ated early due to purulent pericarditis (8 %) or due to a neu-
rosurgical procedure (8 %) (Table 2).
The basic characteristics between patients with early, de-
layed and no corticosteroid therapy are compared in Table 1.
No significant differences regarding age, gender, SAB acqui-
sition and chronic diseases according to McCabe’s classifica-
tion were observed except for rheumatoid arthritis which oc-
curred significantly more often among patients with delayed
initiation of corticosteroid as compared to no corticosteroid
treatment (10 % vs. 1 %, p<0.01). However, the total amount
of patients with rheumatoid arthritis was only 8 (2 %).
Antibiotic therapy
An intravenous antibiotic therapy effective in vitro against the
S. aureus blood isolate was provided to each patient from the
day of positive blood culture. Altogether 272 (75 %) patients
received anti-staphylococcal penicillin (cloxacillin), 69
(19 %) received cefuroxime and 8 (2 %) received vancomycin
(Table 1). No significant difference was observed regarding
the distribution of anti-staphylococcal penicillin or
cefuroxime between the corticosteroid groups whereas vanco-
mycin therapy was provided significantly more often to pa-
tients receiving early (10 %) or delayed (6 %) corticosteroid
therapy as compared to patients treated without corticosteroid
therapy (1 %) (p<0.01). Clindamycin as antibiotic therapy
was received by only 5 (1 %) patients (data not shown).
Fluoroquinolone as additional antibiotic was provided to 205
(57 %) and rifampicin to 210 (58 %) patients with no signif-
icant difference between the corticosteroid groups (Table 1).
Deep infection foci and defervescence
Altogether 297 (82 %) patients had a deep infection focus
diagnosed (Table 1). The vast majority of deep infection foci
(76 %) were diagnosed within three days after the positive
blood culture and verified by bacteriological, radiological or
pathological findings whereas a few pneumonia cases (N=5)
were diagnosed through clinical suspicion only. Patients with
early initiated corticosteroid therapy, as compared to patients
treated without corticosteroid therapy, had significantly more
often pneumonia (60 % vs. 30%, p<0.001) and osteomyelitis
(48 % vs. 32 %, p<0.05). When comparing patients with
delayed initiation of corticosteroid therapy to patients treated
without corticosteroid therapy no significant difference was
Eur J Clin Microbiol Infect Dis (2016) 35:471–479 473
observed in the occurrence of deep infection foci. No differ-
ences in invasive eradication of deep infection foci, i.e. ab-
scess punctuation, surgical focus removal or infected joint
lavage, were observed between the groups either (Table 1).
Mortality
No significant differences in time to defervescence were ob-
served between the groups (Table 1). The total case fatality in
361 patients at 28 days was 8 % and at 90 days 12 %. Patients
with early initiated corticosteroid therapy, as compared to pa-
tients treated without corticosteroid therapy, had significantly
higher mortality at 28 days (20 % vs. 7 %, p<0.05) and at
90 days (30 % vs. 10 %, p<0.001). No difference in mortality
was seen between patients with delayed initiation of cortico-
steroid therapy and patients treated without corticosteroid
therapy (Table 1, Fig. 2).
Mortality was analyzed according to indications for early
corticosteroid therapy (Table 2). Patients with corticosteroid
therapy initiated due to a complicated pulmonary disease had
the highest 90-day mortality (63 %) whereas the correspond-
ing mortality was seemingly lower for patients with cortico-
steroid due to purulent pericarditis (33 %), craniotomia (33 %)
or an immunological phenomenon (17 %). Patients with un-
recorded indication for corticosteroid treatment had a high
mortality of 43 %. No mortality was observed among patients
receiving corticosteroid therapy due to epidural-, para-spinal-
or pre-sacral abscesses (Table 2).
The prognostic impact of early and delayed corticosteroid
therapy was evaluated by univariate analysis and Cox propor-
tional hazards regression analysis (Table 3). In univariate anal-
ysis, parameters for 28-day positive prognostic impact were
McCabe’s healthy-nonfatal underlying conditions (OR 0.16,
p < 0.001) and rifampicin therapy > 14 days (OR 0.27,
p=0.003), whereas age>60 years (OR 11.1, p<0.001), alco-
holism (OR 3.52, p=0.003), endocarditis (OR 2.47, p=0.03),
pneumonia (OR 2.93, p=0.004) and early initiated corticoste-
roid therapy (OR 3.39, p = 0.005) were found as negative
prognostic parameters. Delayed initiation of corticosteroid
therapy had no prognostic impact in 28-day univariate analy-
sis. In Cox proportional hazards regression analysis parame-
ters with positive prognostic impact were McCabe’s healthy-
nonfatal underlying conditions (HR 0.30, p=0.002) and ri-
fampicin therapy> 14 days (HR 0.24, p = 0.003), whereas
age > 60 (HR 10.1, p < 0.001), alcoholism (HR 3.25,
p=0.008), endocarditis (HR 4.49, p<0.001) and early initiat-
ed corticosteroid therapy (HR 3.75, p=0.002) were negative
prognostic parameters (Table 3). When repeating univariate
and Cox proportional hazards regression analysis for 90-day
prognostic parameters the results resembled those of 28-day
prognostic parameters with the exception of chronic renal fail-
ure (HR 2.78, p=0.007), malignancy (HR 2.37, p=0.028)
430 patients with
S. aureus bacteremia 
Exclusion
criteria
361 patients with
S. aureus bacteremia
Severe sepsis or
septic chock
Prednisone >10mg/day or
equivalent for >1 month
269 patients without
corticosteroid therapy
92 patients with
corticosteroid therapy
40 patients with early
corticosteroid initiation
31 patients with delayed
corticosteroid initiation
21 patients with late
corticosteroid initiation
Fig. 1 Study profile. Originally,
430 methicillin-sensitive
S. aureus bacteremia were
recruited. Patients with
corticosteroid therapy equivalent
to prednisone ≥ 10 mg/day
for≥ 1 month prior to positive
blood culture and all patients with
severe sepsis or septic shock were
excluded (N= 69). No cases of
methicillin-resistant S. aureus
were included (N= 6).
Corticosteroid therapy: Early
initiation, i.e. initiation within
week 1 of positive blood cultures
for S. aureus; Delayed initiation,
i.e. initiation within week 2-4 of
positive blood cultures for
S. aureus; Late initiation, i.e.
initiation within week 5–12 of
positive blood cultures for
S. aureus
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Table 1 Characteristics of 340 hemodynamically stabile patients with methicillin-sensitive S. aureus bacteremia (SAB) categorised according to
initiation time-point of adjunctive corticosteroid therapy
Variable No
corticosteroid
(n = 269)
Early
initiation a
(n = 40)
Delayed
initiation b
(n = 31)
Early initiation vs. no corticosteroid Delayed initiation vs. no corticosteroid
OR
(95 % CI)
p-value OR
(95 % CI)
p-value
General characteristics
Age > 60 years 126 (47) 21 (53) 18 (58) 1.25 (0.65–2.44) NS 1.57 (0.74–3.34) NS
Male gender 168 (62) 27 (68) 14 (45) 1.25 (0.62–2.53) NS 0.50 (0.23–1.05) NS
Nosocomial bacteremia 139 (52) 16 (40) 19 (61) 0.62 (0.32–1.23) NS 1.48 (0.69–3.17) NS
Underlying diseases
Healthy-nonfatal c 208 (77) 29 (73) 21 (68) 0.77 (0.37–1.64) NS 0.62 (0.28–1.38) NS
Ultimately-rapidly fatal c 61 (33) 11 (28) 10 (32) 1.29 (0.61–2.74) NS 1.62 (0.73–3.63) NS
Rheumatoid arthritis 4 (1) 1 (3) 3 (10) 1.70 (0.19–15.6) NS 7.10 (1.51–33.3) <0.01
Connective tissue disease 11 (4) 3 (8) 2 (6) 1.90 (0.51–7.14) NS 1.62 (0.34–7.66) NS
Chronic kidney disease 34 (13) 2 (5) 5 (16) 0.36 (0.08–1.58) NS 1.33 (0.48–3.69) NS
Chronic lung disease 37 (14) 10 (25) 5 (16) 2.09 (0.94–4.63) NS 1.21 (0.44–3.34) NS
Malignancy 31 (12) 6 (15) 6 (19) 1.36 (0.53–3.49) NS 1.84 (0.70–4.84) NS
Diabetes 65 (24) 14 (35) 5 (16) 1.69 (0.83–3.43) NS 0.60 (0.22–1.64) NS
HIV-infection 8 (3) 0 0 — — — —
Injection drug use 31 (12) 5 (13) 2 (6) 1.10 (0.40–3.01) NS 0.53 (0.12–2.33) NS
Antibiotic therapy
Cloxacillind 206 (77) 27 (68) 23 (74) NS NS
Cefuroxime d 55 (20) 5 (13) 4 (13) NS NS
Vancomycin d 2 (1) 4 (10) 2 (6) <0.01 <0.01
Fluoroquinolone C 154 (57) 20 (50) 21 (68) NS NS
Rifampicin e 154 (57) 23 (58) 17 (55) NS NS
Rifampicin > 14 days e 124 (46) 15 (38) 14 (45) NS NS
Infection diagnostics
Any deep infection focus f 210 (78) 38 (95) 28 (90) 5.34 (1.25–22.8) <0.05 2.62 (0.77–8.93) NS
Pneumonia f 82 (30) 24 (60) 13 (42) 3.42 (1.73–6.78) <0.001 1.65 (0.77–3.52) NS
Endocarditis f 39 (14) 5 (13) 8 (26) 0.84 (0.31–2.28) NS 2.05 (0.86–4.91) NS
Septic arthritis f 33 (12) 6 (15) 5 (16) 1.26 (0.49–3.24) NS 1.38 (0.49–3.83) NS
Osteomyelitis f 85 (32) 19 (48) 11 (35) 1.96 (1.00–3.83) <0.05 1.19 (0.55–2.60) NS
Any deep abscess f 113 (42) 22 (55) 16 (52) 1.69 (0.87–3.29) NS 1.47 (0.69–3.10) NS
Abscess drainage 67 (25) 15 (38) 11 (35) 1.81 (0.90–3.63) NS 1.66 (0.76–3.64) NS
Surgical focus removal 59 (22) 13 (33) 11 (35) 1.71 (0.83–3.53) NS 1.96 (0.89–4.32) NS
Infected joint lavage 8 (3) 0 0 — — — —
Outcome
Time to defervescence g 4.32 ± 5.39 4.15 ± 6.12 4.35 ± 3.16 — — NS
Mortality within 28 days 20 (7) 8 (20) 2 (6) 3.11 (1.27–7.65) <0.05 0.86 (0.19–3.86) NS
Mortality within 90 days 26 (10) 12 (30) 3 (10) 4.01 (1.82–8.81) <0.001 1.00 (0.29–3.52) NS
Originally, altogether 430 SAB patients were identified. Patients with corticosteroid therapy equivalent to prednisone ≥ 10 mg/day for ≥ 1 month prior to
positive blood culture and all patients with severe sepsis or septic shock receiving systemic corticosteroid as part of sepsis therapy at blood culture
collection time-point were excluded (N= 69). Twenty-one patients had corticosteroid therapy initiated 4 weeks past positive blood culture and these were
not included in the analysis. Data are no. (%) of patients unless otherwise specified. NS non-significant
a Corticosteroid therapy initiation within week 1 of positive blood culture for S. aureus
b Corticosteroid therapy initiation within week 2-4 of positive blood culture for S. aureus
c According to McCabe and Jackson [31]
d Standard antibiotic therapy
e Additional antibiotic therapy
f Diagnosed within 90 days time
g Time given in days (mean ± SD)
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and delayed initiation of corticosteroid therapy (HR 2.32,
p=0.014) associating to negative prognosis in univariate anal-
ysis (data not shown).
As a further investigation, we performed a Cox proportion-
al hazards regression analysis including only patients with
chronic pulmonary disease or SAB related pneumonia
(N=164). The results of this analysis closely resemble those
of Table 3 with a 90-day negative prognostic impact due to
early initiated corticosteroid therapy (HR 2.94, p= 0.008).
This prognostic impact was further accentuated when includ-
ing only patients receiving early initiated corticosteroid thera-
py with a minimum of prednisone 100 mg/week (HR 4.65,
p<0.001).
Discussion
The main finding of our study was a significantly poorer out-
come among SAB patients receiving early initiated corticoste-
roid therapy as compared to those treated without corticoste-
roid therapy or with corticosteroid therapy at a later stage.
Patients treated with early initiated corticosteroid therapy
had a more than 3-fold higher hazard ratio for a fatal outcome
when adjusting for all prognostic factors.
Parameters with indisputable prognostic impact in SAB are
immunosuppression, severity of illness at blood culture col-
lection time-point and proper antibiotic therapy [4, 22, 33].
Immunosuppressive therapy (including corticosteroid thera-
py) prior to positive blood culture is known to deteriorate
the prognosis of SAB [3–6, 22]. SAB patients suffering from
severe sepsis or septic shock present with high mortality [4, 7,
22] and systemic corticosteroids are widely applied as sepsis
therapy despite controversial results in large clinical trials.
Furthermore, prognosis of SAB is impaired by delayed proper
antibiotic therapy [33]. MRSA is connected to delayed effec-
tive antibiotic therapy and poorer outcome [6, 9, 34] and van-
comycin therapy is known to increase the risk for persistent
and recurrent SAB and to impair prognosis as compared to
beta-lactam antibiotic therapy [35, 36]. In the present study
patients with early corticosteroid therapy received significant-
ly more often vancomycin therapy as compared to patients
treated without corticosteroid therapy or patients with delayed
corticosteroid therapy. However, altogether only 8 (2 %) pa-
tients received vancomycin therapy and the low n-number did
not allow for reliable statistical analyses. Thus, we were not
able to evaluate the prognostic impact of vancomycin treat-
ment among patients with corticosteroid therapy.
This study excluded patients with corticosteroid therapy
equivalent to prednisone≥10 mg/day for≥1 month prior to
positive blood culture results and included only hemodynam-
ically stabile patients. No MRSA cases were included and all
patients were provided with an effective antibiotic therapy
from the time-point of the first positive blood culture and only
Table 2 Categorization of 40
hemodynamically stabile patients
with S. aureus bacteraemia (SAB)
according to indication for
adjunctive corticosteroid therapy
started within a week after
positive blood culture
Indication for
corticosteroid use
Patient number
(n = 40)
3-day
mortality
28-day
mortality
90-day
mortality
1. Purulent pericarditis 3 (8) 0 0 1 (33)
2. Craniotomy 3 (8) 0 0 1 (33)
3. Epidural, para-spinal or pre-sacral abscess 7 (17) 0 0 0
4. Complicated pulmonary disease a 8 (20) 0 5 (63) 5 (63)
5. Activation of autoimmune disease b 12 (30) 0 1 (8) 2 (17)
6. Other indication 7 (17) 0 2 (29) 3 (43)
Data are number (%) of patients
a Chronic obstructive pulmonary disease, asthma bronchial or pulmonary obstruction.
b Earlier diagnosed autoimmune disease
Fig. 2 Kaplan-Meier analysis of 28-day survival of 340 Staphylococcus
aureus bacteremia patients categorized according to corticosteroid
therapy (log-rank 0.04). Patients with corticosteroid therapy equivalent
to prednisone ≥ 10 mg/day for≥ 1 month prior to positive blood culture
and all patients with severe sepsis or septic shock at blood culture
collection time-point were excluded (N= 69). No cases of methicillin-
resistant S. aureus were included (N= 6). Corticosteroid therapy: Early
initiation, i.e. within week 1 of positive blood culture for S. aureus;
Delayed initiation within weeks 2-4 of positive blood culture; Late
initiation within weeks 5–12 of positive blood culture
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2 % received vancomycin. Hence, we were able to analyze the
impact of corticosteroid therapy in hemodynamically stabile
SAB without any external interfering corticosteroid therapy
and without any bias or delay in proper antibiotic therapy
onset.
However, our study has several weaknesses which have to
be taken into account when the results are interpreted.
Although the patients were followed prospectively they were
not randomized according to corticosteroid treatment.
Complicated pulmonary diseases and pneumonia in associa-
tion with SAB has been described as a powerful parameter for
poor outcome [3, 22, 37, 38]. This was observed also in the
present study as patients with early corticosteroid treatment
due to pulmonary complications demonstrated very high
(63 %) mortality rates.
It may be argued that patients with early initiated cortico-
steroid therapy had a more severe form of SAB, including a
more pessimistic prognosis initially, and thus weremore prone
to receive corticosteroid therapy at an early phase. To further
investigate this argument a Cox proportional hazards regres-
sion analysis was performed including only patients with
chronic pulmonary disease or SAB related pneumonia and
within this subgroup of patients early initiated corticosteroid
therapy had an evident negative prognostic impact which was
further accentuated when including only patients receiving
early initiated corticosteroid therapy with a minimum of pred-
nisone 100mg/week. Another major bias is the low number of
patients with early corticosteroid therapy in the various
indication groups not making it possible to analyze them with
statistical testing. However, as corticosteroids are not general-
ly indicated for SAB treatment, randomized studies would not
be ethically justifiable. We think that our study, despite it’s
weaknesses, has a clear message to clinicians to overweigh
the indications of corticosteroid treatment carefully in the ear-
ly treatment of SAB.
Various attempts were made to control reasons for the dif-
ferences in outcome between patients with early and delayed
initiation of corticosteroid therapy and patients treated without
corticosteroid therapy. Differences in age, bacteremia acquisi-
tion, underlying conditions or antibiotic therapy did not ex-
plain the poorer prognosis. Patients with deep infection foci,
including pneumonia and osteomyelitis, were more prone to
receive early initiated corticosteroid therapy as compared to
patients treated without corticosteroid therapy. Parameters
with independent prognostic impact have been identified in
earlier studies, e.g. age>60–65 years [1, 38], severe underly-
ing diseases [1, 36], adjunctive rifampicin therapy [30], chron-
ic alcoholism [4, 22] and endocarditis [1, 22]. When control-
ling for all of these parameters early initiated corticosteroid
therapy remained an independent prognostic marker for 28
and 90 days fatal outcome.
The exclusion of patients with corticosteroid therapy prior
to SAB diagnosis and the inclusion of only hemodynamically
stabile patients have inevitably influenced the results as im-
munosuppressive therapy, severe sepsis and septic shock as-
sociate to high mortality [4, 7, 22, 33]. Furthermore, each
Table 3 Cox proportional hazards regression model for prognostic factors of 28-day mortality in S. aureus bacteremia patients (N = 340)
Variable Univariate analysis OR (95 % CI) p-value Multivariate analysis HR (95 % CI) p-value
Age > 60 years 11.1 (3.31–37.4) <0.001 10.1 (2.93–34.8) <0.001
Nosocomial bacteremia 0.96 (0.45–2.02) NS
Healthy-nonfatal underlying disease a 0.16 (0.08–0.36) <0.001 0.30 (0.14–0.65) 0.002
Alcoholism 3.52 (1.45–8.57) 0.003 3.25 (1.36–7.79) 0.008
Any malignancy 2.42 (0.97–6.02) NS
Rifampicin therapy > 14 days b 0.27 (0.11–0.67) 0.003 0.24 (0.09–0.61) 0.003
Endocarditis 2.47 (1.07–5.70) 0.03 4.49 (1.94–10.4) <0.001
Pneumonia 2.93 (1.37–6.30) 0.004
Corticosteroid, early initiation c 3.39 (1.39–8.25) 0.005 3.75 (1.60–8.79) 0.002
Corticosteroid, delayed initiation d 0.74 (0.17–3.28) NS
Originally altogether 430 SAB patients were identified. Patients with corticosteroid therapy equivalent to prednisone ≥ 10 mg/day for ≥ 1 month prior to
positive blood culture and all patients with severe sepsis or septic shock at blood culture collection time-point were excluded (N= 69). Patients were
grouped according to time-point of corticosteroid treatment initiation: 40 patients had early corticosteroid initiation, 31 patients had delayed corticosteroid
initiation and 21 patients had late corticosteroid initiation. Patients with late corticosteroid initiation were not included in the analyses. Hazards ratio (OR)
and 95 % confidence intervals (95 % CI) are presented. NS non-significant
a According to McCabe and Jackson [31]
b Additional antibiotic therapy
c Corticosteroid therapy initiation within week 1 of positive blood culture for S. aureus
d Corticosteroid therapy initiation within week 2-4 of positive blood culture for S. aureus
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patient was provided with a formal infectious disease special-
ist consultation which is known to improve treatment results
and prognosis [1, 3, 39]. Altogether, these factors have most
probably contributed to an overall lower mortality of only 8 %
at 28 days and of 12 % at 90 days as compared to earlier
studies presenting 28–30 days and 90 days mortality figures
of 16–26 % [5, 38–40] and 12–32 %, respectively [1, 2].
However, although the overall mortality in the present study
was low, a negative prognostic impact due to early corticoste-
roid treatment was evident.
In conclusion, our data suggests that in hemodynamical
stabile SAB early initiation of corticosteroid therapy may be
associated to poor outcome as compared to delayed initiation
of corticosteroid therapy or no corticosteroid therapy. The au-
thors encourage caution regarding early use of corticosteroids
in the management of hemodynamical stabile SAB patients.
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